01790oam 2200493 450 991071501710332120210402093054.0(CKB)5470000002507836(OCoLC)1224541481(OCoLC)1227256921(EXLCZ)99547000000250783620201130d2020 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierFairness in Orphan Drug Exclusivity Act report (to accompany H.R. 4712)[Washington, D.C.] :[U.S. Government Publishing Office],[2020]1 online resource (11 pages)Report / 116th Congress, 2d session, House of Representatives ;116-572"November 16, 2020."Includes bibliographical references.Fairness in Orphan Drug Exclusivity Act Drug developmentEconomic aspectsUnited StatesBuprenorphineTherapeutic useUnited StatesOrphan drugsGovernment policyUnited StatesDrugsPricesGovernment policyUnited StatesDrugsLaw and legislationUnited StatesOrphan drugsUnited StatesRare diseasesUnited StatesLegislative materials.lcgftDrug developmentEconomic aspectsBuprenorphineTherapeutic useOrphan drugsGovernment policyDrugsPricesGovernment policyDrugsLaw and legislationOrphan drugsRare diseasesGPOGPOBOOK9910715017103321Fairness in Orphan Drug Exclusivity Act3527578UNINA